In Brief
Refine Search
Pharmaceutical
UK-based Pharmanovia has expanded its endocrinology portfolio with a licensing agreement for Ghryvelin (macimorelin), a new medicine used for diagnosing adult growth hormone deficiency (AGHD) from US biopharma Aeterna Zentaris. 16 March 2023
Biotechnology
A new gene editing company, Seamless Therapeutics, has launched in Germany with $12.5 million in seed financing from investors including Wellington Partners and Forbion. 16 March 2023
Biotechnology
Delaware, USA-based precision oncology firm Prelude Therapeutics has entered into a clinical trial collaboration with Sino-American biotech BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in hematologic malignancies. 15 March 2023
Pharmaceutical
Industry analyst Future Market Insights has forecast that the global market for psychedelic medicines, which it estimates to be currently worth $3.1 billion, will be worth over $14 billion by 2033. 14 March 2023
Biotechnology
South Korean biopharma company Celltrion has announced a joint research and development agreement with Genuv, a Seoul-based biotech. 14 March 2023
Pharmaceutical
Japanese pharma majors Takeda and Shionogi will each receive about 130 million yen ($9.7 million) from the Japanese GHIT Fund to invest in malaria drugs development, according to a GHIT announcement issued on March 13. 14 March 2023
Biotechnology
At a press conference last week, executives of Japanese drug major Eisai forecast $7 billion 1 trillion yen ($7.3 billion) forecast worldwide sales by 2030 for its recently US-approved Alzheimer’s treatment Leqembi (lecanemab), assuming broader coverage from the Centers for Medicare and Medicaid Services (CMS), which has so far limited the use of any amyloid-targeted Alzheimer’s drugs to clinical trials. 11 March 2023
Pharmaceutical
Spanish drugmaker PharmaMar says it has received the Temporary Authorization for the commercialization of Zepzelca (lurbinectedin) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy without central nervous system (CNS) metastases. 10 March 2023
Biotechnology
Kyowa Kirin has ended a decade long licensing agreement with fellow Japanese drugmaker OncoTherapy' Science’s subsidiary Immunas Pharma for the asset KHK6640, a potential Alzheimer's treatment. 10 March 2023
Biosimilars
Generics and biosimiliars company Sandoz has signed a memorandum of understanding to build a new biologics production plant in Slovenia, with an expected investment of over $400 million. 9 March 2023
Pharmaceutical
The trade group for UK-based drugmakers, the Association of the British Pharmaceutical Industry (ABPI), has appointed vice president Susan Rienow to the role of president. 9 March 2023
Pharmaceutical
The US Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. 8 March 2023
Biotechnology
The board of directors of US biotech major Biogen has elected Caroline Dorsa as chairwoman, effective immediately following the company’s 2023 Annual Meeting of Stockholders, set to take place on June 14, 2023. 8 March 2023
Biotechnology
Singaporean biotech Hummingbird Bioscience has exercised an option to license a new HER3-targeted antibody from Cancer Research Horizons, the innovation arm of Cancer Research UK. 7 March 2023
Biotechnology
Gene therapy company Voyager Therapeutics has received a milestone payment of $25 million after Novartis exercised its options to license two novel capsids. 6 March 2023
Biotechnology
US biopharma company Incyte announced late Friday that it will discontinue its Phase III LIMBER-304 trial, sending its share price 2% lower early in Monday’s trading. 6 March 2023
Biotechnology
The Japanese subsidiary of US biotech major Biogen and Japanese drugmaker Eisai have terminated the Japan co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments, effective March 31, 2023. 3 March 2023
Pharmaceutical
Japanese pharma company Alfresa has entered into a licensing deal with K Pharma to develop and commercialize ropinirole in Japan for the treatment of amyotrophic lateral sclerosis (ALS). 3 March 2023
Pharmaceutical
The US Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). 2 March 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk just announced plans to expand its research and development (R&D) presence in the greater Boston, USA, metro area, creating one of its largest R&D hubs outside of Denmark. 2 March 2023
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
San Diego-based Cidara Therapeutics, a biotech using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has entered into a securities purchase agreement with certain investors to raise up to around $105 million. 21 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
Eli Lilly is not resting on its laurels when it comes to the fast-growing field of obesity treatments, an area in which it is already a leader. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
Biotechnology
Astellas Pharma has been hit by bad news from the US Food and Drug Administration, which will not currently approve the firm’s request to supplement the label for Izervay (avacincaptad pegol). 21 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
Sage Therapeutics will down tools on its dalzanemdor program, after the Phase II DIMENSION trial missed both primary and secondary endpoints. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Biotechnology
HCW Biologics has announced a worldwide licensing agreement with WY Biotech to develop and commercialize one of its preclinical immunotherapy candidates. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
US clinical-stage biotech Vyriad has entered into a strategic collaboration with Swiss pharma giant Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. 21 November 2024
Biotechnology
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. 20 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze